Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that oral tofacitinib was effective and well tolerated for treating alopecia areata in most pediatric patients, with nearly 73% experiencing hair regrowth.

In this study, IGF-I was shown to enhance human hair follicle growth, maintain the anagen phase, and increase expression of certain growth factors and anti-apoptotic markers.

This study found that in participants with notalgia paresthetica, 8 weeks of treatment with difelikefalin significantly improved itch intensity and increased the rate of strict complete response compared to placebo, starting as early as week 3.

This case report describes a 46-year-old man diagnosed with frontal fibrosing alopecia, a condition primarily affecting postmenopausal women, highlighting its rare occurrence in men.

In this study, tofacitinib treatment for six months significantly reduced hair loss severity in alopecia areata patients.

This review discusses fibrosing frontal alopecia, including its causes, mechanisms, and treatments, and emphasizes the need for further research to improve understanding and treatments; it reports no new clinical results.

This report describes a case where a woman with frontal fibrosing alopecia initially presented with symptoms resembling rosacea, but further investigation led to a diagnosis of FFA, resulting in a treatment change to oral finasteride and hydroxychloroquine.

This review discusses the potential of Janus kinase inhibitors as a promising new treatment for alopecia areata, suggesting they could become a first-line therapy in the future, but reports no new clinical results.

In this open-label trial, tofacitinib showed dramatic clinical responses in most patients with moderate-to-severe alopecia areata, supporting further research into JAK inhibitors for this condition.

In this review, cosmetic practices such as non-ablative lasers, autologous fat injections, and oral isotretinoin may help alleviate certain symptoms of frontal fibrosing alopecia, while treatments like deep chemical peels and ablative laser therapies are contraindicated due to potential scarring risks.

This article discusses the potential role and mechanisms of platelet-rich fibrin therapies in androgenetic alopecia management, exploring their possible benefits over existing treatments but reports no new clinical results.

This letter discusses the emerging use of Janus kinase inhibitors, specifically oral tofacitinib, for treating alopecia areata in children, but reports no new clinical findings.

In this open-label study of post-menopausal women with frontal fibrosing alopecia, researchers found that 12 weeks of baricitinib monotherapy significantly reduced disease activity as measured by the Lichen Planopilaris Activity Index, improved patient-reported scalp hair growth, but showed no significant change in eyebrow growth.

In this open-label trial, Tofacitinib was well tolerated and improved IFN and cytokine scores, as well as overall skin pathology, in individuals with Down syndrome and immune skin conditions.

This study found that early intervention and treatment with intralesional triamcinolone acetonide may stabilize hairline recession in patients with frontal fibrosing alopecia, although further research is needed for definitive treatment guidelines.

This study found that Ifidancitinib, a JAK1/3 inhibitor, significantly promoted hair regrowth and reduced inflammation in a mouse model of alopecia areata by decreasing pathogenic T cell activity and inducing T cell exhaustion.

This study found that ICAM-1 expression in murine skin is developmentally regulated and crucial for skin and hair follicle remodeling beyond its recognized role in immune responses.

This study developed the Alopecia Areata Patient Priority Outcome (AAPPO), a new tool designed to measure and capture the symptoms and impacts of alopecia areata that matter most to patients.

This study observed distinct post-marketing safety signal patterns for baricitinib and tofacitinib in adult AA, influenced by their differing regulatory uses and real-world contexts, and emphasizes the need for future studies to validate these findings.

This study analyzed 24 Japanese cases of fibrosing alopecia in a pattern distribution and found a distinctive "parachute" hair loss pattern, emphasizing unique clinical characteristics potentially influenced by racial factors.

In this study, researchers analyzed adverse event reports from the FAERS database to identify safety concerns associated with ipilimumab in elderly patients, noting common issues like gastrointestinal events and new signals such as orchitis and alopecia areata, with timing influenced by body weight.

This study from North-East India analyzed 21 cases of frontal fibrosing alopecia, noting a high prevalence in post-menopausal women and distinct histological features such as perifollicular lymphocytic infiltrate and hydropic degeneration.

This study suggests that early initiation of treatment in fibrosing alopecia in a pattern distribution may lead to a more favorable outcome, as evident in some patients experiencing arrested disease progression and hair regrowth.

Dermoscopy helps diagnose frontal fibrosing alopecia by identifying specific scalp features.

This research developed new in vitro models for high-throughput screening of drugs that could protect or restore immune privilege in hair follicles, finding that Tofacitinib was effective in preventing inflammation-related marker upregulation, while Tacrolimus and αMSH worked specifically in outer root sheath keratinocytes.

This study found that the film-trigger applicator system enhanced drug delivery efficiency and skin penetration of dissolving microneedles compared to traditional patch systems in both lab and animal models.

In this study, oral tofacitinib treatment led to significant hair regrowth and changes in skin and blood biomarkers in a patient with alopecia areata.

Certain drugs and supplements may contribute to hair loss in the frontal hairline in older women.

In this retrospective study, tofacitinib was found to be effective and well-tolerated for treating severe alopecia areata, with 77% of patients achieving a clinical response over 4-20 months, though results were more favorable for patients with less extensive hair loss.